Clinical Challenges and Case Studies of Microorganisms in Pneumonias
The Challenge to Health Care Providers

HIGHLIGHTS OF A SYMPOSIUM

Clinical Cases in Health Care-Associated Pneumonia
Angeline A. Lazarus, MBBS, FCCP
Professor of Medicine
Uniformed Services University of the Health Sciences
Bethesda, Md.

Evolution of Health Care-Associated Pneumonia Continues
Richard G. Wunderink, MD, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Northwestern University, The Feinberg School of Medicine
Chicago, Ill.

Guideline Recommendations for Diagnosis of Pneumonia
Stanley B. Fiel, MD, FCCP
Professor of Medicine
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
Newark, NJ

Treatment Strategies for Community-Acquired Pneumonia
Ronald F. Grossman, MD, FCCP
Professor of Medicine, University of Toronto
Respirologist, Credit Valley Hospital
Mississauga, Ontario, Canada

Supported by an educational grant from Wyeth

Sponsored by
This program is based on presentations from a continuing medical education satellite symposium that took place on October 20-25, 2007, in Chicago, Ill.

This supplement was produced by the medical education department of Elsevier Society News Group, a division of Elsevier International Medical News Group. Neither the editors of CHEST PHYSICIAN, the Editorial Advisory Board, nor the reporting staff contributed to its content. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter or of the Publisher.

Copyright © 2008 Elsevier, Inc. and the American College of Chest Physicians. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Elsevier, Inc. and the American College of Chest Physicians will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

ACCREDITATION STATEMENT
Sponsored by the American College of Chest Physicians (ACCP). The ACCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This product fulfills the ACCP Learning Category II: Self-Directed.

The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair and others, as appropriate, to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available during all educational activities.
FACULTY DISCLOSURE STATEMENT

The following faculty members of the Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers supplement have disclosed to the ACCP that a relationship does exist with the respective company/organization as it relates to their material and should be communicated to the participants of this educational activity:

Angeline A. Lazarus, MBBS, FCCP
Dr Lazarus has received speakers bureau honorarium during 2006 from sanofi-aventis.

Richard G. Wunderink, MD, FCCP
Dr Wunderink has received an investigator initiated grant from Eli Lilly and Company and has performed clinical research for Novartis Pharmaceuticals Corporation, who sponsored a study for which a revised manuscript has been submitted for publication. He has worked as a consultant and researcher for Inverness Medical Innovations, Inc., and has stated that he will reference their diagnostic test.

Stanley B. Fiel, MD, FCCP
Dr Fiel has received funding from Parion Sciences, Genentech, and Novartis, and has received funding as a consultant, speaker, or advisor from GlaxoSmithKline, Boehringer Ingelheim Pharmaceuticals, Inc., and Novartis.

Ronald F. Grossman, MD, FCCP
Dr Grossman has received funding as an advisor for GlaxoSmithKline, Bayer, Ortho-McNeil, Inc., and sanofi-aventis.

DISCLAIMER

The American College of Chest Physicians ("ACCP") and its officers, regents, executive committee members, members, related entities, employees, representatives, and other agents (collectively, "ACCP Parties") are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any ACCP publication and the use or reliance on any such content. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the ACCP parties be liable for any direct, indirect, incidental, special, or consequential damages, or lost profits that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

OBJECTIVES

- Identify three common epidemiologic data references related to pneumonia and other associated infectious diseases.
- Understand key evidence-based recommendations on the diagnosis of health care-associated pneumonias.
- Assess appropriate antibiotic and nonantibiotic use based upon case-based questions.

STATEMENT OF NEED

Despite a broad use of antimicrobials available to treat pneumonia, it remains the eighth leading cause of death in the United States. In 1999, the age-adjusted death rate due to influenza and pneumonia was 23.6 per 100,000 persons. Current estimates of the incidence of community-acquired pneumonia range from 4 to 5 million cases per year, with about 25% requiring hospitalization. Nosocomial pneumonia is estimated to occur in 250,000 persons per year, representing about 15% to 18% of all nosocomial infections. Streptococcus pneumoniae remains the most commonly identified pathogen in community-acquired pneumonia. A variety of other pathogens have been reported to cause pneumonia in the community, with their order of importance dependent on the location and population studied. These include long-recognized pathogens such as Haemophilus influenzae, Mycoplasma pneumoniae, and influenza A, along with newer pathogens such as Legionella species and Chlamydophila pneumoniae. Other common causes in the immunocompetent patient include Moraxella catarrhalis, Mycobacterium tuberculosis, and aspiration pneumonia. The causative agent in community-acquired pneumonia remains unidentified in 30% to 50% of cases. Pathogens, such as meticillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Pseudomonas aeruginosa (MDR PA), and Burkholderia cepacia, are increasingly recognized causes of pneumonia. Severe acute respiratory syndrome (SARS)-associated coronavirus emerged and spread worldwide in the winter of 2002 to 2003. This virus, and its associated SARS, is another pathogen with growing importance.

TARGET AUDIENCE

Pulmonary Fellows-in-Training, Critical Care Fellows-in-Training, Physicians-Pulmonary, Critical Care, and General Medicine, Respiratory Therapists, Advance Critical Care Nurse Practitioners, and Physician Assistants.

ESTIMATED TIME OF COMPLETION:

90 MINUTES

TERM OF APPROVAL

Release Date: April 2008
Expiration Date: April 30, 2009

DESIGNATION STATEMENT

The American College of Chest Physicians designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Anyone who attended the “Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers” session at CHEST 2007 when this content was presented, and who already claimed CME credit for this presentation, cannot claim CME from this enduring product.

CME INSTRUCTIONS

1) Go to www.chestnet.org and click on the “CME Certificates” bar highlighted in red.
2) Enter your ACCP ID number and click submit, OR, if you do not have an ACCP ID number, click on link “Need to Create an Account.”
3) Under “Available CME” find the product code 6717 and click the “CME” link to the right of the program title.
4) If prompted for one, enter the CME Access Code provided to you EXACTLY as it appears: 212296.6717.MONO.
5) Complete any required post-test and/or survey.
6) Print out the CME certificate found under “Your Current CME History.”
7) If you encounter any problems or have questions, please send an e-mail to CME@chestnet.org or contact the ACCP CME verification mailbox at 1-847-498-8376.
8) CME Start Date is April 2008 and CME End Date is April 30, 2009.

Participants will read this monograph and then participate in an online post-test and evaluation form.

Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers 3
Introduction

Current Issues and Challenges in Pneumonia

The clinical environment of pneumonia in the United States offers a study in contrasting facts. Since the early days of the 20th century, pneumonia mortality has declined by more than 90% from about 180 deaths per 100,000 in 1900 to about 40 per 100,000 today. However, pneumonia-associated mortality has remained largely unchanged for the past 50 to 60 years.

Pneumonia remains a leading cause of death in the United States, accounting for almost 50,000 fatalities annually. Between two and three million cases of pneumonia are diagnosed each year, leading to 500,000 hospital admissions annually. Although mortality is generally less than 1% among patients requiring only outpatient treatment, the risk of death increases by tenfold or more among patients requiring hospital admission. Intensive care unit (ICU) care is associated with a mortality risk of 30% to 40% in patients with severe pneumonia.

Continual expansion of the antibiotic armamentarium has given physicians more options than ever for controlling and eradicating bacterial causes of pneumonia. Unfortunately, pneumonia-associated pathogens continue to mutate, evolve, and otherwise morph into variants that are increasingly difficult to eradicate, even with the unprecedented spectrum of antibiotic options available to physicians and their patients. According to the Centers for Disease Control and Prevention, the proportion of nosocomial (particularly ICU-related) infections involving methicillin-resistant Staphylococcus aureus has increased to about 50% of the total at many medical centers in the United States.

Pneumonia classifications also have begun to overlap and blur, complicating physicians’ attempts to arrive at an accurate diagnosis and assess the disease severity. Many patients with pneumonia have no recent history of hospitalization, but they often have been in contact with health care providers in clinics, offices, and other settings. As a result, the distinction between community-acquired pneumonia (CAP) and nosocomial (or hospital-acquired) pneumonia (HAP) has become less rigid. This has given rise to the term health care-associated pneumonia (HCAP), which may have features of both CAP and HAP.

In some pneumonia studies, HCAP has been the predominant form of illness. From a microbiologic perspective, HCAP more closely resembles HAP or ventilator-associated pneumonia (VAP). HCAP also tends to cause more severe illness compared with CAP.

The changing clinical environment of pneumonia has put even greater onus on clinicians to make timely diagnoses and initiate appropriate therapy as soon as possible. Clinical guidelines recommend starting therapy within 12 hours of presentation, citing data demonstrating increased morbidity and mortality risks associated with delayed therapy.

The risks of delayed appropriate therapy are matched by the risks of starting a patient’s treatment with inappropriate therapy. Initial inappropriate or ineffective treatment independently predicts an increased mortality risk that might be as much as fourfold or fivefold greater compared with patients who receive initial appropriate therapy.

Physicians can turn to several recently promulgated and updated clinical guidelines for direction in navigating the risks, uncertainties, and conundrums related to diagnosing and treating pneumonia. Adherence to recognized clinical guidelines significantly improves outcomes of patients compared with nonadherence to guidelines.

The following educational activity addresses the challenging issues surrounding recognition and management of pneumonia. In the presentations that follow, infectious disease specialists offer their knowledge and insights into current issues and standards related to bacterial pneumonia. Clinicians involved in the care of patients with pneumonia will find the information timely and readily applicable to clinical practice.

References

Clinical Cases in Health Care-Associated Pneumonia

Angeline A. Lazarus, MBBS, FCCP
Professor of Medicine
Uniformed Services University of the Health Sciences
Bethesda, Md.

Introduction
Pneumonia remains a leading cause of morbidity and mortality in the United States. However, early recognition and diagnosis followed by initiation of effective treatment with appropriate antibiotics can improve pneumonia outcomes. Understanding the different types of pneumonia can lead to prompt recognition of the most likely causative organisms and their potential resistance patterns. The following clinical cases illustrate differences in presentation and symptoms that can guide physicians toward a correct pneumonia diagnosis and prompt initiation of appropriate therapy.

CASE I
A 34-year-old female with a history of asthma, worsening wheeze, and nonproductive cough

Presentation and History
The patient has a 30-year history of asthma and presented for evaluation of worsening wheeze and increased nonproductive cough over a 2-week period. She had a fever for the first 3 days but no chills, chest pain, nausea, or vomiting. She returned from a 1-week vacation in Puerto Rico 60 days ago.

Current medications consist of multiple therapies for asthma and allergies. The patient has no history of hospitalization, no asthma-related emergency department visits in the past 2 years, no history of pneumonia, and no prior surgery. She is a nonsmoker and rarely drinks alcohol.

Physical/Clinical Findings
The patient has a temperature of 99.7°F, respiration of 18/min, heart rate of 87 bpm, and O2 saturation of 97%.

Cardiac exam is normal. Nasal congestion is noted. The patient is not in acute distress and appears alert. Auscultation reveals bilateral wheezing, but she has no rales. The remainder of the physical exam is normal.

Laboratory
The patient has a white blood cell count of 9900 and a neutrophil count of 78.

The rest of her laboratory findings were within normal ranges.

Radiographic Findings
Chest x-rays were consistent with a diagnosis of pneumonia. The x-ray shows evidence of pneumonia in the left upper lobe (Figure 1).

Miscellaneous
The patient was unable to produce a sputum sample. Records from an examination in 2006 showed a normal IgE and no evidence of allergic bronchopulmonary aspergillosis.

Management and Outcome
The patient began outpatient treatment with levofloxacin. Additionally, she took prednisone for 5 days. She continued all existing medications. Patient's symptoms responded promptly, and at 2-week follow-up, her lungs were clear on auscultation and x-ray (Figure 2).

CASE II
A 68-year-old female with a 2-day history of fever, cough, and pleuritic chest pain

Presentation and History
The patient has mild non-insulin requiring diabetes for which she is being treated. She is a nonsmoker and occasionally drinks alcohol. She had knee replacement surgery 60 days ago and spent 2 weeks at a rehabilitation facility. She had a chest x-ray for evaluation of the presenting symptoms.

Physical/Clinical Findings
The patient has a temperature of 100.6°F, heart rate of 96 bpm, respiratory rate of 18/min, and O2 saturation of 97%.

The patient appears alert and oriented with no evidence of distress. Auscultation revealed right lower lobe rales.

Clinical Management and Follow-Up
The patient was prescribed levofloxacin (500 mg/day) for CAP and sent home. Two days later the patient presented to the emergency room with increasing cough, fever, chest pain, and dyspnea. She had a temperature of 101.8°F, heart rate of 124 bpm, respiratory rate of 24/min, O2 saturation of 92%, and blood pressure of 110/76 mmHg. White count was 18000 with left shift, and she had a BUN of 32. The patient was admitted to the hospital for failure of outpatient therapy for CAP (Figure 3).

Laboratory
Microbiologic assessment revealed gram-positive cocci in clusters (Figure 4) and Staphylococcus aureus growth on culture.

Treatment/Clinical Course
The patient was treated with vancomycin when sensitivity results demonstrated methicillin-resistant S. aureus. After a 10-day course of vancomycin, the patient improved and was discharged home.
CASE III
A 71-year-old Hungarian man with a 5-day history of fever, chills, malaise, and lightheadedness

Presentation and History
The patient presented for evaluation of the above-mentioned symptoms. His wife, a pediatrician, had given him azithromycin 4 days previously. He had a 1-day history of drenching night sweats and mild dyspnea. Symptom onset was 1 day after a trip to Arizona, which included a 12-hour layover and 8-hour stay at a Red Cross shelter because of bad weather. At the shelter, he was exposed to sick patients. Two weeks prior to the onset of his illness, the patient had a brief exposure to a sandstorm, also in Arizona. The patient has a history of hypertension, hypolipidemia, and gastro-esophageal reflux disease. He underwent excision of an acoustic neuroma in 1977, complicated by facial droop, vocal cord paralysis, and dysarthria. He also has undergone cervical vertebroplasty.

Current medications include lisinopril, simvastatin, omeprazole, and a multivitamin.

Physical Examination
The patient had a temperature of 102.4°F, heart rate of 98 bpm, respiratory rate of 18/min, and O2 saturation of 96%. The patient was alert and oriented but appeared tired. He had no postural hypotension. Lung examination revealed decreased breath sounds in the right lower lobe with egophony and rales. The cardiac and abdominal examinations were normal.

Laboratory
The patient had a CBC of 9300 and neutrophil count of 83. Blood chemistry was normal. Blood cultures are pending. Induced sputum tested negative for acid-fast bacilli and fungi. Gram stain showed mixed flora (Figure 5).

Radiographic
The patient’s primary care physician requested an x-ray, as well as a chest CT, to rule out pulmonary embolism. The chest x-ray and CT findings were consistent with pneumonia.

Management and Follow-Up
The patient refused bronchoscopy and hospital admission. Treatment was initiated with levofloxacin (750 mg/day) plus clindamycin for possible aspiration pneumonia. Over the next 2 days, cough and fever decreased slightly, but the patient continued to have drenching night sweats. Tests for respiratory syncytial virus, Legionella pneumophila, and Influenza A and B antigen were all negative. Urine and blood cultures also were negative.

On day 3 after initial presentation, the patient returned and reported slightly reduced cough but persistence of drenching sweats and fever. His CBC had increased to 14500 and his neutrophil count to 86. Repeat chest CT revealed increased consolidation.

The patient was admitted to the hospital, and bronchoscopy was scheduled for the next day. A repeat induced-sputum analysis revealed coccidioides sphaeules. The patient began treatment with itraconazole and was discharged home 2 days after admission. Symptoms resolved gradually except for persistent mild cough (Figure 6).

CASE IV
A 44-year-old female ophthalmologist with a 1-week history of cough and upper respiratory symptoms

Presentation and History
The patient presented to the emergency department when she developed a fever (102.5°F) and chills. Within 30 minutes, the patient complained of dizziness and was transferred to the ICU. A chest x-ray was consistent with pneumonia (Figure 7).

The patient had a history of mild persistent asthma treated with combined β-agonist/corticosteroid medication. She had a history of allergy to sulfa. She was a nonsmoker and had an estimated wine consumption of 2 to 3 glasses weekly. Her family history was unremarkable.

Laboratory
The patient had a white count of 31200 and neutrophil count of 60. Her hemoglobin was 10.9 and her hematocrit was 32. She had a pH of 7.3, O2 of 300 on 100% oxygen, bicarb of 14, and PCO2 of 32.

Management and Follow-Up
Emergency room physicians initiated combined antibiotic therapy with vancomycin, levofloxacin, and doxycycline. In the ICU, bronchoscopy and bronchoalveolar lavage revealed gram-positive cocci in pairs. Drotrecogin-alfa was added to the patient’s therapy. Subsequent analysis of BAL specimens revealed Strepococcus pneumoniae with sensitivity to levofloxacin.

After 2 days in the ICU, the patient was extubated. She required continuous positive airway pressure (CPAP) for 4 days and then was transferred to a general unit (Figure 8). She was discharged home on day 9. She was ambulating well and had an O2 saturation of 96%. Figure 9 shows the patient’s chest x-ray at her 1-month follow-up.
Evolution of Health Care-Associated Pneumonia Continues

Richard G. Wunderink, MD, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, Ill.

Introduction
Historically, pneumonia syndromes have been classified into a few discrete categories, such as hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and pneumonia in the immunocompromised patient. The syndromes were treated as distinct entities. However, the lines of demarcation between syndrome categories began to blur, as groups of patients that overlapped the categories emerged. A prime example is nursing home community-acquired pneumonia, which has been treated as a separate entity by some authors and investigators. Subsequently, other pneumonia syndromes emerged with features of CAP but associated with pathogens generally found in the hospital, including multidrug-resistant (MDR) pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumanii, Pseudomonas aeruginosa, and antibiotic-resistant gram-negative enterics. This overlap between HAP and CAP has given rise to the newer concept of health care-associated pneumonia (HCAP). Additional overlap could be seen between HCAP and pneumonia of immunocompromised patients. HIV-infected patients offered a prime example. The number of clinical circumstances included under the HCAP umbrella continued to increase, until HCAP became the predominant pneumonia syndrome, more or less by default.

Epidemiology of Health Care-Associated Pneumonia
Traditionally, pneumonia that develops outside a hospital is categorized as CAP, even among patients who have received medical care outside of a hospital. Few studies have examined the epidemiology of HCAP, but the available data suggest that health care-associated infections have characteristics that make them distinct from CAP.

A review of hospital records on 4,543 patients with culture-positive pneumonia at 59 centers showed that half the patients had CAP and more than 20% had HCAP. Patients categorized as having HCAP had a mortality of 19.8%, almost double the 10% mortality among patients with CAP and slightly greater than the 18.8% mortality among patients with HAP (P<0.001 for comparisons versus CAP). Patients with ventilator-associated pneumonia (VAP) had the highest mortality (29.3%).

HCAP patients more often had pathogens found in VAP than in CAP: methicillin-resistant S. aureus, P. aeruginosa, A. baumanii, and enterics. Some MDR pathogens were more common in patients with HCAP than in those with VAP.

A study of patients with severe, culture-proven nursing home-acquired pneumonia emphasized the role of antibiotic therapy in the development of MDR pneumonia. The study focused on patients admitted to ICUs and requiring mechanical ventilation. During a 36-month period, 88 nursing home patients met criteria for inclusion. In 17 (19%) of the cases, at least one MDR pathogen was recovered from the lower respiratory tract. The frequency of MDR pathogens was 10 times greater (71% vs 7%) in patients with a recent history of antibiotic therapy compared with patients who had not been treated recently with antibiotics (Table 1).

The study of severe nursing home-acquired pneumonia included an evaluation of activities of daily living (ADL). Patients were assigned ADL scores based on a scale that rated a patient’s ability (1 to 3) to perform certain activities, such as feeding, bathing, dressing, and toilet use. A patient with a total score of 6 is fully independent.

Among patients with no recent history of antibiotic therapy, an ADL score <12.5 was associated with absence of MDR pathogens versus 17% in those who had

Table 1. Risk Factors for MDR Pathogens

<table>
<thead>
<tr>
<th>Risk Factor for MDR Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial therapy in preceeding 90 days</td>
</tr>
<tr>
<td>Current hospitalization ≥5 days</td>
</tr>
<tr>
<td>High frequency of antibiotic resistance in community or specific hospital unit</td>
</tr>
<tr>
<td>Presence of risk factors for HCAP</td>
</tr>
<tr>
<td>≥2 days hospitalization in previous 90 days</td>
</tr>
<tr>
<td>Nursing home or extended care facility residence</td>
</tr>
<tr>
<td>Home infusion therapy or wound care</td>
</tr>
<tr>
<td>Chronic dialyses for &gt;30 days</td>
</tr>
<tr>
<td>Family member with MDR</td>
</tr>
</tbody>
</table>

an ADL ≥12.5. In the patients with prior antibiotic therapy, MDR pathogens were isolated from 42% of patients with an ADL <12.5 and 90% of those with an ADL ≥12.5.2

The primary implication of the ADL findings is that a thorough history is essential to the classification and management of patients with nursing home-acquired pneumonia. The more independent a patient is, the less likely the patient is to have MDR pathogens. As a patient’s inability to perform self-care increases, so does the likelihood of MDR pneumonia.

Two recent studies have provided much-needed information about the etiology of pneumonia in patients at risk for HCAP. Spanish investigators prospectively evaluated patients presenting to a hospital with pneumonia over a 4-year period.3 The researchers found that 126 of 727 (17.3%) patients met their criteria for HCAP.

Comparison of patients with HCAP versus CAP showed that the two groups differed substantially. Patients with HCAP were significantly older (69.5 vs 63.7 years, P<0.001), had greater comorbidity (95.2% vs 74.7%, P<0.001), and were significantly more likely to be classified as high risk by the pneumonia severity index (67.5% vs 48.8%, P<0.001).3

Evaluation of individual risk factors demonstrated a higher prevalence in HCAP patients in every instance. The risk factors examined included chronic obstructive pulmonary disease, prior stroke, a history of cancer, long-term corticosteroid therapy, influenza vaccination, and recent antibiotic therapy. As previously stated, patients with HCAP also had a significantly higher pneumonia severity index score.3

The microbiology of HCAP and CAP also differed in the Spanish study. Streptococcus pneumoniae was the most commonly isolated pathogen in both HCAP patients (27.8%) and CAP patients (33.9%). However, Hemophilus influenzae was twice as common in HCAP (11.9% vs 6%). Aspiration was the source of pneumonia in 20.6% of HCAP patients compared with 3% of the CAP patients. Gram-negative bacteria and S. aureus were uncommon in both groups but occurred more often in HCAP patients. About one third more CAP patients had no identifiable pathogen than did HCAP patients (43.9% vs 32.5%).3

Another study published last year described characteristics of 639 culture-positive pneumonia patients who presented to a single US hospital over a 3-year period.4 In contrast to the Spanish study, two thirds of the patients (67.4%) met criteria for HCAP. The major risk factor for HCAP was previous hospitalization (93.3%), particularly hospitalization within the past 90 days (70%). Additionally, the Spanish study excluded severely immunocompromised patients, whereas 39.2% of the HCAP patients in this study were severely immunosuppressed. Other major pneumonia risks in this population included nursing home residence (28.1%) and hemodialysis (10%).

The US study also differed microbiologically from the Spanish investigation. S. pneumoniae accounted for 40.9% of CAP cases but only 10.4% of HCAP patients. S. aureus was the single most common pathogen in HCAP patients (43.9% vs 25.5%), and P. aeruginosa was isolated from 35.5% of HCAP patients versus 6.7% of CAP patients. Gram-negative organisms were isolated from 19.7% of HCAP patients and from 11.6% of CAP patients.

What Is HCAP?
The previous discussion leads to an obvious question: Exactly what is HCAP? The question does not have a straightforward answer. Instead, the answer depends on issues such as the type of hospital, local definitions of HCAP, and community-defined risk factors for HCAP (Table 2).

What is clear is that giving pneumonia patients inappropriate initial empiric antibiotic therapy can have major consequences. Several studies have shown that the mortality risk associated with VAP increases substantially when a patient is started on inappropriate therapy. For example, Celis and colleagues5 reported a 92% mortality in patients who were given inappropriate initial therapy for VAP. Similarly, Luna and colleagues6 found that inappropriate initial treatment was associated with a mortality of 82%. Pneumonia patients frequently receive inappropriate initial antimicrobial therapy. Various studies have demonstrated rates of inappropriate therapy ranging from about 20% to more than 70%.

As a corollary, delayed initiation of appropriate antibiotic therapy also increases the mortality risk in patients with VAP. One prospective observational study examined the impact of delaying initial appropriate antibiotic therapy by

Table 2. What Is Real HCAP?

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Overestimation of aspiration</td>
</tr>
<tr>
<td>• Dependent on hospital</td>
</tr>
<tr>
<td>• Dependent on definition</td>
</tr>
<tr>
<td>• Major issue is culture negative cases</td>
</tr>
</tbody>
</table>

Source: Richard G. Wunderink, MD, FCCP

HCAP = hospital-acquired pneumonia.
more than 24 hours. Of 107 patients included in the study, 33 (30.8%) had delays in therapy of 24 hours or more after meeting diagnostic criteria for VAP. The most common reason for delayed therapy was a delay in writing orders for antibiotic therapy (25 of 33, 75.8%). The average duration of delay was 28.6 hours compared with 12.5 hours for patients whose appropriate therapy was not delayed. Patients who started appropriate treatment within 24 hours of presentation had a 12% mortality. In contrast, delaying initial appropriate therapy for 24 hours or longer more than doubled the mortality risk (28%).

Summary

HCAP is a helpful concept for categorizing, evaluating, and managing pneumonia patients. However, the definitions currently in use should be revisited and refined to make HCAP a more definitive, accurate, and clinically useful designation. Current clinical guidelines have applied HCAP too broadly, making it the predominant pneumonia category, when evidence to support this is lacking. The meaning of HCAP and its influence on clinical management will likely be a driving force behind eventual revision and updating of guidelines for CAP and VAP. Much-needed information about HCAP is starting to emerge to help distinguish the condition more clearly from other pneumonia syndromes. Until recently, HCAP has applied primarily to hospitalized patients. Whether the criteria for the HCAP designation are appropriate for nursing home patients and those discharged from emergency departments remains undetermined. The key issue that should not be overlooked in the discussion of pneumonia categories is the increasing problem posed by drug-resistant organisms. Resistance continues to increase regardless of what category is applied to a pneumonia syndrome.

References


Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers

Table 3. Empiric Treatment—MDR Risk

<table>
<thead>
<tr>
<th>Potential Pathogens</th>
<th>Recommended Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• P. aeruginosa</td>
<td>• Ceftriaxone</td>
</tr>
<tr>
<td>• A. baumannii</td>
<td>• Quinolone (moxifloxacin, ciprofloxacin, levofloxacin)</td>
</tr>
<tr>
<td>• Methicillin-resistant S. aureus</td>
<td>• Ampicillin/sulbactam</td>
</tr>
<tr>
<td>• Antibiotic-resistant (ESBL containing)</td>
<td>• Imipenem,meropenem</td>
</tr>
<tr>
<td>Gram negative enterics</td>
<td>• Piperacillin/tazobactam Plus</td>
</tr>
<tr>
<td>– Klebsiella pneumonia</td>
<td>• Aminoglycoside</td>
</tr>
<tr>
<td>– Enterobacter sp.</td>
<td>• Ciprofloxacin, levofloxacin Plus</td>
</tr>
<tr>
<td>• Legionella pneumophila</td>
<td>• Linezolid</td>
</tr>
<tr>
<td></td>
<td>• Vancomycin</td>
</tr>
<tr>
<td></td>
<td>• (macrolide, quinolone)</td>
</tr>
</tbody>
</table>


Table 4. Empiric Treatment—No MDR Risk

<table>
<thead>
<tr>
<th>Potential Pathogens</th>
<th>Recommended Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• S. pneumoniae</td>
<td>• Ceftriaxone</td>
</tr>
<tr>
<td>• H. influenzae</td>
<td>• Quinolone (moxifloxacin, ciprofloxacin, levofloxacin)</td>
</tr>
<tr>
<td>• Methicillin-sensitive S. aureus</td>
<td>• Ampicillin/sulbactam</td>
</tr>
<tr>
<td>• Antibiotic-sensitive Gram negative enterics</td>
<td>• Imipenem,meropenem</td>
</tr>
<tr>
<td>– E. coli</td>
<td>• Piperacillin/tazobactam Plus</td>
</tr>
<tr>
<td>– Klebsiella pneumonia</td>
<td>• Aminoglycoside</td>
</tr>
<tr>
<td>– Enterobacter sp.</td>
<td>• Ciprofloxacin, levofloxacin Plus</td>
</tr>
<tr>
<td>• Proteus sp.</td>
<td>• Linezolid</td>
</tr>
<tr>
<td>• Serratia marcesans</td>
<td>• Vancomycin</td>
</tr>
</tbody>
</table>

Guideline Recommendations for Diagnosis of Pneumonia

Introduction
Recognition of clinical and microbiologic features of pneumonia syndromes has led to development of clinically useful categories and definitions, such as hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP). Diagnostic testing of patients with suspected pneumonia plays a role in categorization of pneumonia syndromes, but the two principal purposes of diagnostic testing are to (1) determine whether a patient has pneumonia; and (2) determine the etiologic pathogen of the illness.1 Timely diagnosis and determination of the pathogenic culprit are essential to rapid progression to the next step in clinical management: early, aggressive antibiotic therapy with broad-spectrum coverage. Increasingly, initiation of appropriate therapy without delay has emerged as the most prominent factor in eradicating the infectious organism, resolving symptoms, avoiding prolonged hospitalization, and reducing morbidity and mortality associated with pneumonia. Less consensus surrounds the equally important issue of when to stop antibiotic therapy.

Approach to Diagnosis
The American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines for management of HAP, VAP, and HCAP state that pneumonia should be suspected if a patient has new, persistent, or progressive infiltrates on x-ray. Clinical findings suggestive of infection include new onset of fever, purulent sputum, leukocytosis, and a decline in oxygenation (Table 1).1 In one study of diagnostic criteria, radiographic evidence of new or persistent pulmonary infiltrates plus the presence of two of three clinical findings (fever or hypothermia, leukocytosis or leukopenia, and purulent endotracheal aspirate) proved its accuracy for diagnosing VAP.2 That combination constitutes a fairly low diagnostic threshold but nonetheless represents an accurate approach for deciding to initiate empiric antibiotic therapy.

Enumerating the goals of diagnostic strategies, the ATS/IDSA guidelines state that the approach to diagnosis should:1
- Identify patients who have pulmonary infection
- Ensure collection of appropriate cultures
- Promote use of early, effective antibiotic therapy
- Identify patients who have extrapulmonary infection

The guidelines discourage initiation of antibiotic treatment for simple colonization. Additionally, clinicians should remain mindful of the fact that routine monitoring of tracheal aspirate cultures can create misleading impressions. Moreover, the sensitivity of positive blood cultures is less than 25%. Vigilance should be maintained for organisms originated in extrapulmonary sources, even in patients with VAP. Among intubated patients, the lower respiratory tract should be sampled for culture whenever pneumonia is suspected.1

A comprehensive medical history and physical examination help define the severity of HAP. The chest radiograph also is helpful in defining the severity of pneumonia and its complications. Preferred views are posteroanterior and lateral if a patient is not intubated.1

Purulent tracheobronchitis may mimic HAP and VAP and might require antibiotic therapy. However, randomized trials are needed to determine the value of antibiotics in such patients.2

Clinical indications of tracheobronchitis include a fever without any other obvious cause, new or increased sputum production, and a positive tracheal aspirate culture without x-ray evidence of new pneumonia. In a study of 2,128 mechanically ventilated patients, 10.6% were diagnosed with nosocomial tracheobronchitis (NTB). The condition was diagnosed more often in surgical versus medical patients (15.3% vs 9.9%), and the most commonly isolated pathogen was Pseudomonas aeruginosa (~30%). Medical patients with NTB had a higher mortality (36% vs 32.1%), longer stay in the ICU (33.4 days vs 12.8 days), and a longer duration of mechanical ventilation (20 days vs 8.8 days) compared with patients who did not have NTB.3

Tracheal colonization is common in intubated patients and does not indicate infection in the absence of clinical findings. Additionally, tracheal colonization does not require diagnostic evaluation or therapy.1 For all patients with VAP, the ATS/IDSA guidelines recommend collection of blood cultures. A positive culture can indicate pneumonia or extrapulmonary infection. Thoracentesis should be performed to rule out empyema or parapneumonic effusion if a patient has a large pleural effusion or if the effusion appears toxic.1

Samples of lower respiratory tract secretions should be examined before changing antibiotic therapy for patients with suspected HAP or VAP. In the absence

Table 1. Diagnostic Testing

<table>
<thead>
<tr>
<th>Diagnosis suspected if:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- New or progressive radiographic infiltrate</td>
<td></td>
</tr>
<tr>
<td>- Clinical findings suggest infection</td>
<td></td>
</tr>
<tr>
<td>- New onset of fever</td>
<td></td>
</tr>
<tr>
<td>- Purulent sputum</td>
<td></td>
</tr>
<tr>
<td>- Leukocytosis</td>
<td></td>
</tr>
<tr>
<td>- Decline in oxygenation</td>
<td></td>
</tr>
</tbody>
</table>


---

Stanley B. Fiel, MD, FCCP

Professor of Medicine
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
Newark, NJ

Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers
of any clinical suspicion of HAP or VAP and nosocomial tracheobronchitis, respiratory tract cultures should not be obtained.1

Professional opinions vary about the best approach to sampling the lower respiratory tract. A clinical approach probably prevails throughout much of the United States, but a more aggressive bacteriologic approach tends to predominate. Investigators in a large Canadian study examined the issue by comparing two general strategies for lower respiratory tract sampling.4

The study involved 740 patients enrolled in 28 ICUs in Canada and the United States. Patients who had suspected VAP after 4 days in an ICU were randomized to undergo bronchoalveolar lavage (BAL) and quantitative culture of BAL fluid or endotracheal sampling and nonquantitative culture of aspirate. Patients with known colonization or infection with Pseudomonas species or methicillin-resistant Staphylococcus aureus were excluded.

Empiric antibiotic therapy was initiated in all cases until culture results were available. At that point, a protocol of targeted therapy was used to discontinue or reduce the dose or number of antibiotics, or to resume antibiotic treatment of a pre-enrollment condition if the culture was negative. The primary outcome was 28-day mortality.

The results showed no difference between the two diagnostic approaches for the primary endpoint, as the 28-day mortality was 18% to 20% in both groups. The BAL and endotracheal-aspiration groups had similar rates of targeted therapy, days alive without antibiotics, maximum organ dysfunction score, and length of stay in the ICU and hospital.

Clinical Pulmonary Infection Score (CPIS)
The CPIS offers a reasonably simplified approach to evaluation of patients with suspected pneumonia. The CPIS combines four types of information from which a diagnostic score can be derived for an individual patient (Table 2).5 The score is determined by the cumulative score resulting from the combination of clinical, radiographic, physiologic, and microbiologic data. A score of 6 or higher has good correlation with the presence of pneumonia, as defined by quantitative cultures of bronchoscopic and nonbronchoscopic BAL specimens.1

The CPIS has been found to have a sensitivity of 77% and a specificity of 42% compared with a reference standard of histology plus immediate postmortem quantitative lung cultures.1 The addition of gram stain of deep respiratory tract culture to the algorithm improves the sensitivity and specificity. When using a clinical strategy based on the CPIS, the decision to treat on the basis of serial clinical evaluations should be assessed again by day 3 or sooner.1 Patients who have a CPIS score ≤6 for 3 days provides an objective criterion for selecting patients at low risk for discontinuation of empiric treatment of HAP. However, this approach still requires validation in patients with more severe forms of VAP.1

Routine use of the CPIS in clinical practice can help guide the decision to discontinue use of antibiotics. Reliance on individual patient scores can lead to earlier discontinuation of antibiotics, a point that cannot be overemphasized. Starting appropriate antibiotic therapy as quickly as possible leads to better pneumonia outcomes, but knowing when to stop antibiotics is equally important and often more difficult to determine.

A negative tracheal aspirate without a recent change in antibiotics has a strong negative predictive value for VAP. That negative finding should lead to a search for alternative explanations for fever.1

Other Strategies—Procalcitonin
Procalcitonin has been evaluated extensively as a means of differentiating sepsis from non-infectious causes of systemic inflammatory response syndrome (SIRS). However, a recent systematic review of 18 published studies demonstrated a

---

**Table 2. Clinical Pulmonary Infection Score**

<table>
<thead>
<tr>
<th>Component</th>
<th>Value</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temperature °C</td>
<td>≥36.5 and ≤38.4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>≥38.5 and ≤38.9</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>≥39.0 and ≤36.0</td>
<td>2</td>
</tr>
<tr>
<td>Blood leukocytes per mm³</td>
<td>&gt;4000 and ≤11,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&lt;4000 and &gt;11,000</td>
<td>1</td>
</tr>
<tr>
<td>Tracheal secretions</td>
<td>Few</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Large</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Purulent</td>
<td>+1</td>
</tr>
<tr>
<td>Oxygenation</td>
<td>≥240 or presence of ARDS</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>≤240 and absence of ARDS</td>
<td>2</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>No infiltrates</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Patchy or diffuse infiltrates</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Localized infiltrate</td>
<td>2</td>
</tr>
</tbody>
</table>

Source: Luna CM et al.5 Reprinted with permission.
Table 4. HAP, VAP, or HCAP Suspected

<table>
<thead>
<tr>
<th>Late Onset (&gt; 5 days) or Risk Factors for Multi-Drug Resistant (MDR) Pathogens</th>
<th>Limited Spectrum Antibiotic Therapy</th>
<th>Broad Spectrum Antibiotic Therapy for MDR Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HAP = hospital-acquired pneumonia; VAP = ventilator-associated pneumonia; HCAP = healthcare-associated pneumonia.

Summary

Several diagnostic strategies can be employed in the evaluation of patients with suspected HAP, VAP, or HCAP. Regardless of the strategy chosen, the goals remain the same: identifying patients with pulmonary infection, appropriate culture collection, promotion of early and effective antibiotic therapy, and identification of patients with extrapulmonary infection. Invasive and noninvasive diagnostic strategies appear to offer comparable accuracy, and use of either diagnostic approach should lead to appropriate treatment and no difference in mortality. The ATS/IDSA guidelines provide a straightforward diagnostic algorithm that can help keep the chosen diagnostic strategy focused on the principal goals.

References


Bacteriologic Strategies

The ATS/IDSA guidelines recommend qualitative cultures on endotracheal aspirates or samples collected bronchoscopically or nonbronchoscopically. Each technique has its own diagnostic threshold and methodologic limitations. The choice of technique depends on local expertise, experience, availability, and cost. Bacteriologic studies are required before initiating or changing therapy for any patient. Acceptable sampling techniques include tracheal aspirate, BAL, and protected specimen brush (PSB) (Table 3 on page 11). Of note, studies of the impact of diagnostic strategies on antibiotic use and outcomes in patients with suspected VAP have failed to demonstrate a difference in mortality with invasive techniques (BAL or PSB) compared with quantitative or semiquantitative endotracheal culture techniques.

Algorithm for Clinical Management

The ATS/IDSA guidelines include a diagnostic algorithm that essentially summarizes the preceding discussion in a graphic format (Table 4). The algorithm is applicable to the evaluation of patients with suspected HAP, VAP, or HCAP.

One reasonably sized study stands out as a possible exception to the lack of difference between invasive and clinical evaluation of patients. In that study, an invasive strategy was associated with significantly lower 14-day mortality, significantly lower sepsis-related organ failure assessment scores on day 3 and day 7, significantly less antibiotic use at day 28, and significantly more antibiotic-free days.

One reasonably sized study stands out as a possible exception to the lack of difference between invasive and clinical evaluation of patients. In that study, an invasive strategy was associated with significantly lower 14-day mortality, significantly lower sepsis-related organ failure assessment scores on day 3 and day 7, significantly less antibiotic use at day 28, and significantly more antibiotic-free days.

Clinical Challenges and Case Studies of Microorganisms in Pneumonias: The Challenge to Health Care Providers
Diagnostic and Prognostic Issues

Causative pathogens for CAP have no distinctive clinical features that would aid in diagnosis. As a consequence, an ongoing need exists for improved diagnostic technology.

*Streptococcus pneumoniae* continues to play a dominant role in the bacteriology of CAP. Data from 26 prospective studies involving 5,961 patients in 10 countries showed that *S. pneumoniae* was the pathogen most often associated with CAP, accounting for almost 30% of the cases (Figure 1). A meta-analysis of 127 study cohorts comprising 33,148 patients showed that the mortality risk associated with *S. pneumoniae* pneumonia increased from 6.4% among outpatients to 8.3% in hospitalized patients and to 18.6% in patients with *S. pneumoniae* bacteremia. Mortality then doubled to 37% in patients requiring ICU care.

Several schema have been developed to risk-stratify patients, particularly strategies to identify patients with a high mortality risk. One of simplest strategies is the British CURB-65 rule, a modified version of the British Thoracic Society approach to risk stratification. The CURB-65 is essentially a scale that allocs one point to each of five risk factors for mortality in CAP: confusion, urea >7 mmol/L, respiratory rate ≥30/min, blood pressure (<90 mmHg systolic or ≤ 60 mmHg diastolic), and age ≥65.

By the CURB-65 rule, a score of 0 or 1 is associated with a mortality of <2%, representing patients who might be suitable for home management. A CURB-65 score of 2 is associated with an intermediate mortality risk of 9%, representing patients who warrant consideration for hospitalization. A CURB-65 score of 3 or greater indicates a mortality risk of 19%, representing patients with severe CAP that requires hospital management and possible ICU admission.

In North America, the PORT prediction rule was developed to identify low-risk patients with CAP, especially those capable of home management. The PORT system assigns points for demographic variables,
Table 1. Modified ATS/IDSA Criteria of Severity

<table>
<thead>
<tr>
<th>Any 3 of 9 baseline (minor) clinical parameters:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Respiratory rate (l) &gt; 30 breaths/min</td>
</tr>
<tr>
<td>• Confusion/disorientation</td>
</tr>
<tr>
<td>• Uremia (BUN level ≥ 20 mg/dL)</td>
</tr>
<tr>
<td>• Leukopenia (white blood cell count &lt; 4000 cells/mm³)</td>
</tr>
<tr>
<td>• Systolic blood pressure &lt; 90 mm Hg</td>
</tr>
<tr>
<td>• Multilobar infiltrates</td>
</tr>
<tr>
<td>• PaO₂/FiO₂ ratio ≤ 250</td>
</tr>
<tr>
<td>• Thrombocytopenia (platelet count &lt; 100,000 cells/mm³)</td>
</tr>
<tr>
<td>• Hypothermia (core temperature &lt; 36°C)</td>
</tr>
<tr>
<td>• Hypotension requiring aggressive fluid resuscitation</td>
</tr>
</tbody>
</table>

Adapted from Mandell LA et al²

Comorbid conditions, physical observations, and laboratory and radiographic findings. A patient who presents without altered mental status and has a pulse rate <125 bpm, respiratory rate <30/min, systolic blood pressure >90 mm Hg, and a temperature >35°C and <40°C has a class I (lowest) risk designation. Class II comprises patients with a cumulative risk score ≥ 70, increasing to class III for a score of 71 to 90, class IV for 91 to 130 points, and class V for a cumulative risk score >130.

Classes I and II have a mortality risk of <1% and can be potentially managed as outpatients. Class III patients have a mortality risk of 0.9% to 2.8% and may benefit from brief observation in hospital. The mortality increases to 8.5% to 9.3% for class IV, patients who require hospitalization. A cumulative score ≥130 (class V) is associated with a mortality risk of 27.0% to 31.1%, indicative of a patient who may require ICU care.

CAP patients also can be risk-stratified on the basis of need for ICU care. Modified severity criteria in the American Thoracic Society Infectious Diseases Society of America (ATS/IDSA) clinical guidelines identify patients requiring mechanical ventilation and those in septic shock as being in need of ICU care. Additionally, patients who have any three of nine so-called minor clinical parameters at baseline should be admitted to an ICU, according to the ATS/IDSA guidelines (Table 1). These recommendations should be applied with the caveat that they are recommendations based on consensus opinion; none has supporting Level I scientific evidence.

To summarize the utility of the various predictive schema, the predictive power is good and specificity is consistently high, but sensitivity is variable. The true strength of these rules lies in their negative predictive value, the ability to identify patients who do not have a high mortality risk.

Initial Antibiotic Therapy

A multivariate analysis aimed at identifying independent predictors of pneumonia-related mortality revealed ineffective initial therapy as the best mortality predictor, ahead of bacteremia, shock, and other factors. Ineffective initial therapy increased the odds ratio for mortality almost fivefold among patients admitted to an ICU. Subsequently, multiple studies have confirmed the adverse prognostic impact of initial inadequate therapy.

The timeframe for initiating antibiotic therapy also has emerged as a major consideration with implications for prognosis. Much of the emphasis has evolved from studies suggesting that initiation of antibiotic therapy within 4 hours significantly reduces the risk of dying. One frequently cited study examined the relative impact of initiating therapy within 4 hours or later in 18,000 Medicare patients. The data showed that starting antibiotic therapy within 4 hours (versus later) significantly reduced 30-day and in-hospital mortality, as well as the percentage of patients with a hospital length of stay exceeding 5 days (Table 2).

On the surface, the “4-hour rule” appears to be straightforward. A simple process of care can reduce mortality in hospitalized pneumonia patients. However, beneficial actions sometimes are accompanied by unintended consequences, as illustrated by a study published just last year. Following implementation of the 4-hour rule at one Michigan hospital, the proportion of patients receiving antibiotics within 4 hours increased significantly.

However, the percentage of patients with an admission diagnosis of CAP without radiographic abnormalities also increased significantly, as did the number of blood cultures and the per-patient antibiotic use. The percentage of patients with a final diagnosis of CAP decreased significantly as compared to before the 4-hour rule, and implementation of the rule had no effect on the pneumonia severity index, CURB-65 scores, or mortality.

In the simplest terms, the study indicated that many patients received antibiotics when they did not have pneumonia. The results suggest that making an accurate diagnosis supersedes early initiation of therapy as a factor in outcome.

Combination Antibiotic Therapy Versus Monotherapy

For patients with bacteremic pneumococcal pneumonia, does treatment with an antibiotic combination improve outcomes relative to treatment with a single antibiotic? That question has been addressed in several recent studies. In one study, investigators retrospectively evaluated outcomes in 225 patients who received empiric therapy for bacteremic pneumococcal pneumonia. All of the patients had a pneumonia severity index >90. Treatment was classified as single effective therapy, dual effective therapy, or more than dual effective therapy. Patients who received single effective therapy had a mortality approaching 20%, whereas dual effective therapy was associated with a mortality of less than 10%.

Combination therapy for severe CAP was evaluated prospectively in 844 adults with pneumococcal bacteremia. Investigators stratified patients by illness severity, and then examined the type of therapy administered: single-agent versus dual-agent. The two approaches to antibiotic therapy produced similar outcomes in lower-risk patients. However, among the most critically ill patients, dual therapy
Antibiotic Resistance in CAP

The impact of antibiotic resistance in CAP involves three classes of agents: beta-lactams, macrolides, and fluoroquinolones. Data are largely lacking to support the view that resistance is a major issue with beta-lactam therapy. At currently recommended doses and with availability and use of third-generation cephalosporins, beta-lactam antibiotics remain effective in most cases. However, if the minimum inhibitor concentration is ≥4 µg/L, problems with resistance may arise.

Despite widespread use, macrolides appear to maintain their bactericidal efficacy. A body of evidence has begun to emerge, suggesting that resistance is an issue when it involves the pneumococcus. Prior macrolide therapy does appear to increase resistance among pneumococci. Moreover, the degree of resistance appears to vary according to the specific macrolide agent used previously.

The fluoroquinolone resistance story has multiple chapters, whose content varies according to the site of infection (community versus nosocomial or nursing home) and history of fluoroquinolone use. Our experience in Toronto indicates almost no resistance in patients with CAP and no history of fluoroquinolone therapy. When CAP patients have been treated previously with a quinolone, resistance increases but varies according to which quinolone agent was previously used. The situation with nosocomial/nursing home pneumonia and no prior quinolone therapy resembles that of CAP and a positive history for quinolone therapy. Resistance occurs most often in patients with hospital- or nursing home-associated pneumonia and prior quinolone exposure. The frequency of resistance varies greatly according to the specific quinolone agent previously received.

Clinical Guidelines for Pneumonia

In addition to the IDSA and ATS, the Canadian Infectious Disease Society and Canadian Thoracic Society have developed clinical guidelines for pneumonia, as has the British Thoracic Society. The various guidelines have recommended a similar approach to clinical management for the past 15 years or so. After diagnosing pneumonia, the clinician must decide whether treatment can occur on an outpatient basis or whether hospitalization is warranted. Hospitalized patients are further segregated according to the need for ICU care. Finally, all but the British guidelines further categorize patients on the basis of their risk for pseudomonas.

Using the ATS/IDSA guidelines as an example, decisions about initial antibiotic therapy depend upon pre-pneumonia health status, local rates of antibiotic resistance, and history of antibiotic therapy. Patients with a recent history of antibiotic therapy, nosocomial pneumonia patients were evaluated with regard to adherence or nonadherence to clinical guidelines. Patients whose treatment did not follow recommendations had a significantly higher rate of treatment failure (19.7% vs 12.9%, P=0.03) and a significantly higher mortality (8.9% vs 5.4%, P=0.008).

The Therapeutic Future for Severe CAP

Given clear evidence that pneumonia-associated mortality has remained largely unchanged for the past 50 years, new approaches to treatment are warranted. One therapeutic candidate that has been evaluated is recombinant human-activated protein C (drotrecogin-alpha). In a randomized prospective, double-blind trial involving 1,690 patients with sepsis, treatment with drotrecogin-alpha was associated with a lower mortality compared with placebo. Among the patients with pneumonia as the cause for sepsis, a relative decreased risk in mortality of their respiratory tract infection was observed.

Table 2. Effect of Early Administration of Antibiotics on Outcomes

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients</th>
<th>Antibiotics within 4 hours</th>
<th>Antibiotics after 4 hours</th>
<th>Adjusted Odds Ratio</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-day mortality</td>
<td>12.0</td>
<td>11.6</td>
<td>12.7</td>
<td>0.85</td>
<td>.005</td>
</tr>
<tr>
<td>In-hospital mortality</td>
<td>7.0</td>
<td>6.8</td>
<td>7.4</td>
<td>0.85</td>
<td>.03</td>
</tr>
<tr>
<td>% of patients with length of stay &gt;5 days</td>
<td>43.3</td>
<td>42.1</td>
<td>45.1</td>
<td>0.90</td>
<td>.003</td>
</tr>
<tr>
<td>30-day readmission rate</td>
<td>13.4</td>
<td>13.1</td>
<td>13.9</td>
<td>0.95</td>
<td>.34</td>
</tr>
</tbody>
</table>

Adapted from Houck PM et al9
28% was observed at 28 days. Survival benefit was most pronounced in severe CAP patients with S. pneumoniae infection and in severe CAP patients at high risk of death.

Hydrocortisone infusion as an adjunct to antibiotic therapy may also have a role. In a study involving 46 patients with severe CAP, hydrocortisone was administered as a bolus followed by continuous infusion for 7 days. By day 8, patients treated with hydrocortisone had significant improvement in levels of C-reactive protein and significant improvement in oxygenation. Survival to hospital discharge was 70% in patients who received antibiotic therapy alone compared with 100% in patients who received adjunctive hydrocortisone infusion. Patients in the hydrocortisone group also had a significant reduction in duration of mechanical ventilation compared with the placebo group. These observations need to be confirmed in larger trials before these interventions can be accepted as routine management.

Summary

S. pneumoniae remains the most important pathogen in severe CAP. Stratification of patients by illness severity aids selection of appropriate empiric therapy. Rates of bacterial resistance are increasing, and local resistance rates should be factored into the decision-making surrounding initial therapy. Guideline-directed therapy decreases the risk of treatment failure and mortality. Further decreases in pneumonia-associated mortality require therapeutic strategies that include modulation of the immune system.

References


